Genmab A/S (GMAB)
NASDAQ·Healthcare·Biotechnology
$54.71
+2.13%
Mkt Cap $16.79B
Analyst Ratings
No recent rating data.
Price Target (22 analysts)
$38.25
Range $32.00 – $43.00
Implied Upside
-30.1%
Consensus $38.25 vs current $54.71
NASDAQ·Healthcare·Biotechnology
$54.71
+2.13%
Mkt Cap $16.79B
No recent rating data.
Price Target (22 analysts)
$38.25
Range $32.00 – $43.00
-30.1%
Consensus $38.25 vs current $54.71